학술논문
Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy.
Document Type
Academic Journal
Author
Dastoli S; Department of Health Sciences, Magna Graecia University, Catanzaro, Italy.; Passante M; Department of Health Sciences, Magna Graecia University, Catanzaro, Italy.; Loconsole F; Clinical Dermatology, AOU Policlinico Consorziale Bari, Bari, Italy.; Mortato E; Clinical Dermatology, AOU Policlinico Consorziale Bari, Bari, Italy.; Balato A; Unit of Dermatology, University of Campania Luigi Vanvitelli, Naples, Italy.; Piccolo V; Unit of Dermatology, University of Campania Luigi Vanvitelli, Naples, Italy.; Guarneri C; Unit of Dermatology, Department of Biomedical, Dental Sciences and Morphological Imaging (BIOMORF), University of Messina, Messina, Italy.; Macca L; Unit of Dermatology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.; Provenzano E; AO 'Annunziata', Cosenza, Italy.; Valenti G; AO 'Pugliese Ciaccio', Catanzaro, Italy.; D'Amico D; AO 'Pugliese Ciaccio', Catanzaro, Italy.; Micali G; UOC Dermatology Clinic University of Catania, Catania, Italy.; Musumeci ML; UOC Dermatology Clinic University of Catania, Catania, Italy.; Palazzo G; Ospedale Distrettuale di Tinchi Pisticci, Azienda Sanitaria di Matera, Matera, Italy.; Foti C; Unit of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy.; Romita P; Unit of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy.; Fabbrocini G; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.; Megna M; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.; Sammarra I; Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.; Bennardo L; Department of Health Sciences, Magna Graecia University, Catanzaro, Italy.; Patruno C; Department of Health Sciences, Magna Graecia University, Catanzaro, Italy.
Source
Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Long-term real-life data on secukinumab use in psoriasis are limited.
Objectives: Determine the long-term effectiveness of secukinumab in moderate-to-severe psoriasis in real-life.
Methods: Multicenter retrospective study analyzing data from adult patients treated with secukinumab for at least 192 weeks and up to 240 weeks in Southern Italy, between 2016 and 2021. Clinical data, including concurrent comorbidities and prior treatments were collected. Effectiveness was assessed by Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI) scores at the initiation of secukinumab and at weeks 4, 12, 24, 48, 96, 144, 192, and 240.
Results: Two hundred and seventy-five patients (174 males), mean age 50.80 ± 14.78 years, were included; 29.8% had an uncommon localization, 24.4% psoriatic arthritis, 71.6% comorbidities. PASI, BSA, and DLQI improved significantly from week 4 and continued to improve over time. Between weeks 24 and 240, PASI score was mild (≤10) in 97-100% of patients, 83-93% had mild affected BSA (BSA ≤ 3), and 62-90% reported no effect of psoriasis on their quality of life (DLQI 0-1). Only 2.6% of patients reported adverse events and no patient discontinued the treatment during the study period.
Conclusions: Secukinumab effectiveness in the long-term treatment of psoriasis is confirmed in real-world.
Objectives: Determine the long-term effectiveness of secukinumab in moderate-to-severe psoriasis in real-life.
Methods: Multicenter retrospective study analyzing data from adult patients treated with secukinumab for at least 192 weeks and up to 240 weeks in Southern Italy, between 2016 and 2021. Clinical data, including concurrent comorbidities and prior treatments were collected. Effectiveness was assessed by Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI) scores at the initiation of secukinumab and at weeks 4, 12, 24, 48, 96, 144, 192, and 240.
Results: Two hundred and seventy-five patients (174 males), mean age 50.80 ± 14.78 years, were included; 29.8% had an uncommon localization, 24.4% psoriatic arthritis, 71.6% comorbidities. PASI, BSA, and DLQI improved significantly from week 4 and continued to improve over time. Between weeks 24 and 240, PASI score was mild (≤10) in 97-100% of patients, 83-93% had mild affected BSA (BSA ≤ 3), and 62-90% reported no effect of psoriasis on their quality of life (DLQI 0-1). Only 2.6% of patients reported adverse events and no patient discontinued the treatment during the study period.
Conclusions: Secukinumab effectiveness in the long-term treatment of psoriasis is confirmed in real-world.